Chemistry: molecular biology and microbiology – Vector – per se
Reexamination Certificate
2011-06-28
2011-06-28
Burkhart, Michael (Department: 1633)
Chemistry: molecular biology and microbiology
Vector, per se
C435S325000
Reexamination Certificate
active
07968333
ABSTRACT:
The present invention provides adenoviral vectors comprising cell status-specific transcriptional regulatory elements which confer cell status-specific transcriptional regulation on an adenoviral gene. A “cell status” is generally a reversible physiological and/or environmental state. The invention further provides compositions and host cells comprising the vectors, as well as methods of using the vectors.
REFERENCES:
patent: 5648478 (1997-07-01), Henderson
patent: 5677178 (1997-10-01), McCormick
patent: 5698443 (1997-12-01), Henderson et al.
patent: 5770442 (1998-06-01), Wickham et al.
patent: 5801029 (1998-09-01), McCormick
patent: 5830686 (1998-11-01), Henderson
patent: 5834306 (1998-11-01), Webster et al.
patent: 5871726 (1999-02-01), Henderson et al.
patent: 5994128 (1999-11-01), Fallaux et al.
patent: 5998205 (1999-12-01), Hallenbeck et al.
patent: 6057299 (2000-05-01), Henderson
patent: 6197293 (2001-03-01), Henderson et al.
patent: 6254862 (2001-07-01), Little et al.
patent: 6432700 (2002-08-01), Henderson et al.
patent: 6436394 (2002-08-01), Henderson et al.
patent: 6495130 (2002-12-01), Henderson et al.
patent: 6551587 (2003-04-01), Hallenbeck et al.
patent: 6585968 (2003-07-01), Little et al.
patent: 6627190 (2003-09-01), Wold et al.
patent: 6638762 (2003-10-01), Chang et al.
patent: 6676935 (2004-01-01), Henderson et al.
patent: 6692736 (2004-02-01), Yu et al.
patent: 6777203 (2004-08-01), Morin et al.
patent: 6852528 (2005-02-01), Yu et al.
patent: 6900049 (2005-05-01), Yu et al.
patent: 6916918 (2005-07-01), Yu et al.
patent: 6991935 (2006-01-01), Henderson et al.
patent: 7078030 (2006-07-01), Johnson et al.
patent: 7319033 (2008-01-01), Henderson et al.
patent: 7396679 (2008-07-01), Johnson et al.
patent: 7482156 (2009-01-01), Arroyo et al.
patent: 2001/0053352 (2001-12-01), Yu
patent: 2001/0053768 (2001-12-01), Gregory et al.
patent: 2002/0120117 (2002-08-01), Yu
patent: 2002/0136707 (2002-09-01), Yu
patent: 2002/0192187 (2002-12-01), McClelland
patent: 2003/0026792 (2003-02-01), Lamparski
patent: 2003/0039633 (2003-02-01), Yu
patent: 2003/0068307 (2003-04-01), Yu
patent: 2003/0095989 (2003-05-01), Irving et al.
patent: 2003/0104625 (2003-06-01), Cheng et al.
patent: 2003/0152553 (2003-08-01), Little et al.
patent: 2004/0175364 (2004-09-01), McClelland et al.
patent: 2005/0095705 (2005-05-01), Kadan et al.
patent: 2005/0169890 (2005-08-01), Yu et al.
patent: 2009/0297483 (2009-12-01), Henderson et al.
patent: 0845537 (1998-06-01), None
patent: 1147181 (2000-08-01), None
patent: WO 92/03563 (1992-03-01), None
patent: WO 95/11984 (1995-05-01), None
patent: WO 95/14100 (1995-05-01), None
patent: WO 95/19434 (1995-07-01), None
patent: WO 96/17053 (1996-06-01), None
patent: WO 96/34969 (1996-11-01), None
patent: WO 97/01358 (1997-01-01), None
patent: WO-97/01358 (1997-01-01), None
patent: WO 98/06864 (1998-02-01), None
patent: WO 98/13499 (1998-04-01), None
patent: WO 98/13508 (1998-04-01), None
patent: WO 98/14593 (1998-04-01), None
patent: WO 98/35028 (1998-08-01), None
patent: WO 98/39464 (1998-09-01), None
patent: WO 98/39465 (1998-09-01), None
patent: WO 98/39466 (1998-09-01), None
patent: WO 98/39467 (1998-09-01), None
patent: WO 99/06576 (1999-02-01), None
patent: WO 99/25860 (1999-05-01), None
patent: WO 00/15820 (2000-03-01), None
patent: WO 00/46355 (2000-08-01), None
patent: WO 03/007859 (2003-01-01), None
patent: WO 03/104476 (2003-12-01), None
patent: WO 2004/042025 (2004-05-01), None
Result 2 from STIC library search of SEQ ID No. 2, issued patents database, search conducted on Oct. 19, 2007, pp. 1-7.
Neuman et al., Author's Correction: Transcription of the E2F-1 gene is rendered cell cycle dependent by E2F DNA-binding sites within its promoter, Mol Cell Biol. 15(8):4660 (1995).
Abe et al., 1993, “Characterization of Cis-Acting Elements Regulating Transcription of the Human DF3 Breast Carcinoma Associated Antigen (MUC1) Gene,”Proc. Natl. Sci. USA90:282-286.
Adams, et al., 1995, “Transcriptional Control by E3F”, Seminars in Cancer Biology, 6:99-108.
Advanti et al., 1997, Radiogenetic Therapy: On the Interaction of Viraltherapy and Ionizing Radiation for Improving Local Control of Tumors, 24(6):633-638.
Anderson, 1998, Human Gene Therapy,,Nature392:25-30.
Arnberg et al., 1997, “Fiber Genes of Adenoviruses with Tropism for the Eye and the Genital Tract,”Virol. 227: 239-244.
Ausubel et al., eds. 1987,Current Protocols in Molecular Biology Suppl. 30 Sec. 7.7.18, Table 7.7.1.
Babiss et al., 1987, Cellular Promoters Incorporated into the Adenovirus Genome,J. Mol. Biol. 193:643-650.
Bailey et al., 1993, “Enteric Adenovirus Type 40: Expression of EI B Proteins in Vitro and in Vivo,”Virol. 193:631-641.
Bailey et al., 1994, “Cell Type Specific Regulation of Expression from the Ad40 E1B Promoter in Recombinant Ad5/Ad40 Viruses,”Virol. 202: 695-706.
Behringer et al., 1988, “Dwarf Mice Produced by Genetic Ablation of Growth Hormone-Expressing Cells,”Genes Dev. 2: 453-461.
Berkner et al., 1983, “Generation of Adenovirus by Transfection of Plasm ids,”Nuc. Acid Res. 11(17): 6003-6020.
Bett et al., 1993, “Packaging Capacity and Stability of Human Adenovirus Type 5 Vectors,”J. Virol. 67(10): 5911-5921.
Bett et al., 1994, “An efficient and Flexible System for Construction of Adenovirus Vectors with Insertions or Deletions in Early Regions 1 and 3,”Proc. Natl. Acad. Sci. USA9\:8802-8806.
Black, et al., 1999, “Regulation of E2F: A Family of Transcription Factors Involved in Proliferation Control”,Gene, 234:281-302.
Blackwood, et al., 1998, “Going the Distance: A Current View of Enhancer Action”,Science, 281:60-63.
Bridge et al., 1989, Redundant Control of Adenovirus Late Gene Expression by Early Region 4, V.Virol. 63(2): 631-638.
Bristol, et al., 2003, “In Vitro and In Vivo Activities of an Oncolytic Adenoviral Vector Designed to Express GM-CSF”,Molecular Therapy, 7(6):755-764.
Bryan, et al., 1997, “Evidence for an Alternative Mechanism for Maintaining Telemere length in Human Tumors and Tumor-Derived Cell Lines”,Nat. Med. 3(11): 1271-1274.
Bunn et al., 1996, “Oxygen Sensing and Molecular Adaptation to Hypoxia,”Physiol. Rev. 76(3): 839-885.
Cannio et al., 1991, “A Cell-Type Specific and Enhancer-Dependent Silencer in the Regulation of the Expression of the Human Urokinase Plasminogen Activator Gene,”Nuc. Acids Res. 19(9): 2303-2308.
Colditz, 1993, “Epidemiology of Breast Cancer,”Cancer Suppl. 71(4): 1480-1489.
Cuevas, et al., 2003, “Specific Oncolytic Effect of a New Hypoxia-Inducible Factor-Dependent Replicative Adenovirus on von Hippel-Lindau-Defective Renal Cell Carcinomas”Cancer Res., 63:6877-6884.
Curiel, 1999, Strategies to Adapt Adenoviral Vectors for Targeted Delivery,Gene Therapy Strategies, 158-171.
Dachs et al., 1997, “Targeting Gene Expression to Hypoxic Tumor Cells,”Nat. Med. 3(5): 515-520.
Dachs, 1997, Targeted Gene Therapy to Cancer: A Review,Oncolog. Research9:313-325.
Dachs, et al., 1996, “The Molecular Response of Mammalian Cells to Hypoxia and the Potential for Exploitation in Cancer Therapy”,Br. J. Cancer, 74:5126-5132.
Doronin, et al., 2003, “Overexpression of the ADP (E3-11.6K) Protein Increases Cell Lysis and Spread of Adenovirus”,Virology, 305(2):378-387.
Doronin, et al., 2001, “Tissue-Specific, Tumor-Selective, Replication-Competent Adenovirus Vector for Cancer Gene Therapy”,Jour. of Virol., 75(7):3314-3324.
Doronin, et al., 2000, “Tumor-Specific, Replication-Competent Adenovirus Vectors Overexpressing the Adenovirus Death Protein”,Jour. of Virol., 74(13):6147-6155.
Dyson, 1998, “The Regulation of E2F by PRB-Family Proteins”,Genes and Development, 12:2245-2262.
Eck et al., 1996, Gene-Based Therapy—Chapter 5,Goodman&Gilman's The Pharmaceutical Basis of Therapeutics, 9th Ed., McGraw-Hill, pp. 77-101.
Engelhar
Henderson Daniel R.
Yu De-Chao
Burkhart Michael
Cold Genesys, Inc.
Stetina Brunda Garred & Brucker
LandOfFree
Adenovirus vectors containing cell status-specific response... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Adenovirus vectors containing cell status-specific response..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Adenovirus vectors containing cell status-specific response... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2734802